Skye Bioscience Statistics
Total Valuation
Skye Bioscience has a market cap or net worth of $65.69 million. The enterprise value is $6.88 million.
Important Dates
The next estimated earnings date is Friday, August 8, 2025, after market close.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Skye Bioscience has 30.98 million shares outstanding. The number of shares has increased by 201.59% in one year.
| Current Share Class | 30.98M |
| Shares Outstanding | 30.98M |
| Shares Change (YoY) | +201.59% |
| Shares Change (QoQ) | -0.79% |
| Owned by Insiders (%) | 1.57% |
| Owned by Institutions (%) | 40.01% |
| Float | 16.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.85, with a Debt / Equity ratio of 0.01.
| Current Ratio | 11.85 |
| Quick Ratio | 11.14 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -114.08 |
Financial Efficiency
Return on equity (ROE) is -47.27% and return on invested capital (ROIC) is -31.21%.
| Return on Equity (ROE) | -47.27% |
| Return on Assets (ROA) | -28.04% |
| Return on Invested Capital (ROIC) | -31.21% |
| Return on Capital Employed (ROCE) | -60.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.04M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Skye Bioscience has paid $10,071 in taxes.
| Income Tax | 10,071 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.77% in the last 52 weeks. The beta is 1.67, so Skye Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 1.67 |
| 52-Week Price Change | -79.77% |
| 50-Day Moving Average | 1.90 |
| 200-Day Moving Average | 3.26 |
| Relative Strength Index (RSI) | 50.30 |
| Average Volume (20 Days) | 239,493 |
Short Selling Information
The latest short interest is 3.11 million, so 10.05% of the outstanding shares have been sold short.
| Short Interest | 3.11M |
| Short Previous Month | 3.21M |
| Short % of Shares Out | 10.05% |
| Short % of Float | 19.35% |
| Short Ratio (days to cover) | 13.55 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.80M |
| Pretax Income | -42.28M |
| Net Income | -32.65M |
| EBITDA | -35.35M |
| EBIT | -35.80M |
| Earnings Per Share (EPS) | -$0.83 |
Full Income StatementBalance Sheet
The company has $59.22 million in cash and $412,111 in debt, giving a net cash position of $58.81 million or $1.90 per share.
| Cash & Cash Equivalents | 59.22M |
| Total Debt | 412,111 |
| Net Cash | 58.81M |
| Net Cash Per Share | $1.90 |
| Equity (Book Value) | 59.25M |
| Book Value Per Share | 1.91 |
| Working Capital | 57.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.71 million and capital expenditures -$1.61 million, giving a free cash flow of -$31.32 million.
| Operating Cash Flow | -29.71M |
| Capital Expenditures | -1.61M |
| Free Cash Flow | -31.32M |
| FCF Per Share | -$1.01 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Skye Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -201.59% |
| Shareholder Yield | -201.59% |
| Earnings Yield | -49.71% |
| FCF Yield | -47.68% |
Analyst Forecast
The average price target for Skye Bioscience is $16.60, which is 683.02% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.60 |
| Price Target Difference | 683.02% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 33.63% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2023. It was a reverse split with a ratio of 0.004:1.
| Last Split Date | Sep 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.004:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |